Qorvo? Biotechnologies Omnia? SARS-CoV-2 Antigen Test Detects Delta and Other Circulating Variants in Two Studies
November 10, 2021 at 08:00 am EST
Share
Qorvo? announced that two recent studies confirm that the Qorvo Omnia SARS-CoV-2 Antigen Test efficiently detected SARS-CoV-2 variants circulating in the United States. Of the two studies, one was conducted by Emory University, Georgia Institute of Technology, and Children?s Healthcare of Atlanta for the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADxSM) initiative and the other was performed by the Qorvo Biotechnologies Research and Development laboratory in Plymouth, Minnesota. As a RADxSM-supported company, Qorvo regularly validates the Omnia SARS-CoV-2 Antigen Test for new variant response in partnership with the RADxSM variant taskforce. Qorvo also performs internal testing on recombinant antigens with mutations specific to circulating variants. Recent work has focused on the Delta variant given significant national and international interest. Both datasets support the ability to detect all variants tested, and importantly, the Delta variant.
Qorvo, Inc. specializes in the design, production and marketing of radio-frequency components and solutions. In particular, the group makes power amplifiers, embedded modules, selector switches, duplexers, power management devices, wireless connection solutions, frequency convertors, oscillators, couplers and optical components.
Net sales break down by activity as follows:
- mobile terminals and electronic devices (76.3%);
- defense and aeronautics equipment, network infrastructures (23.7%).
At the end of March 2022, the group had 7 production sites located in the United States (3), China (2), Costa Rica and Germany.
Net sales break down geographically as follows: the United States (41.5%), China (32.3%), Taiwan (7.4%), Asia (13.4%) and Europe (5.4%).
QORVO, INC. 
